Prinocate (4 - 8 kg)
ATC code
Species
Large cats (>4-8 kg).
Indications
For cats suffering from, or at risk from, mixed parasitic infections:
The treatment and prevention of flea infestation (Ctenocephalides felis),
The treatment of ear mite infestation (Otodectes cynotis),
The treatment of notoedric mange (Notoedres cati),
The treatment of the lungworm Eucoleus aerophilus (syn. Capillaria aerophila) (adults),
The prevention of lungworm disease (L3/L4 larvae of Aelurostrongylus abstrusus),
The treatment of the lungworm Aelurostrongylus abstrusus (adults),
The treatment of the eye worm Thelazia callipaeda (adults),
The prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immitis),
The treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of Toxocara cati and Ancylostoma tubaeforme).
The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
Dose to be administered and administration route
For external use only (spot-on use).
The recommended minimum doses are 10 mg/kg bodyweight imidacloprid and 1.0 mg/kg bodyweight moxidectin, equivalent to 0.1 ml/kg bodyweight of the veterinary medicinal product.
The treatment schedule should be based on individual veterinary diagnosis and on the local epidemiological situation.
Administer in accordance with the following table:
|
Cats [kg] |
Pipette size to be used |
Volume [ml] |
Imidacloprid [mg/kg b.w.] |
Moxidectin [mg/kg b.w.] |
|
>4-8 |
imidacloprid/moxidectin 80 mg/8 mg spot-on solution for large cats |
0.8 |
10-20 |
1-2 |
|
>8 |
the appropriate combination of pipettes 0.8 ml and 0.4 ml (intended for use in small cats ≤4 kg and ferrets) to provide the recommended dose (the minimum recommended dose is 0.1 ml product/kg bodyweight) |
|||
Flea treatment and prevention (Ctenocephalides felis):
One treatment prevents future flea infestation for 4 weeks. Pre-existing pupae in the environment may emerge for 6 weeks or longer after treatment is initiated, depending upon climatic conditions. Therefore, it may be necessary to combine treatment with this veterinary medicinal product with environmental treatments aimed at breaking the flea life cycle in the surroundings. This can result in a more rapid reduction in the household flea population. The product should be administered at monthly intervals when used as part of a treatment strategy for flea allergy dermatitis.
Treatment of ear mite infestation (Otodectes cynotis):
A single dose of the product should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment. Do not apply directly to the ear canal.
Treatment of notoedric mange (Notoedres cati):
A single dose of the product should be administered.
Treatment of the lungworm Eucoleus aerophilus (syn. Capillaria aerophila) (adults):
A single dose of the product should be administered.
Prevention of Aelurostrongylus abstrusus:
The product should be administered monthly.
Treatment of Aelurostrongylus abstrusus:
The product should be administered monthly for three consecutive months.
Treatment of the eye worm Thelazia callipaeda (adults):
A single dose of the product should be administered.
Heartworm prevention (Dirofilaria immitis):
Cats in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms. Therefore prior to treatment with the product, the advice provided in section 4.5 should be considered.
For prevention of heartworm disease, the product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit heartworm larvae) are present. The product may be administered throughout the year or at least 1 month before the first expected exposure to mosquitoes. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended that the same day or date be used each month. When replacing another heartworm preventative product in a heartworm prevention programme, the first treatment with this product must be given within 1 month of the last dose of the former medication.
In non-endemic areas there should be no risk of cats having heartworm. Therefore they can be treated without special precautions.
Roundworm and hookworm treatment (Toxocara cati and Ancylostoma tubaeforme):
In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective roundworms and hookworms. In areas non-endemic for heartworm, the product can be used as part of a seasonal prevention programme against fleas and gastrointestinal nematodes.
Method of administration:
1. Remove the pipette from its packaging. Hold the pipette in an upright position, twist and pull the cap off.
2. Turn the cap around and place the other end of the cap back on the pipette. Push and twist the cap to break the seal, then remove the cap from the pipette.
3. Part the coat on the animal’s neck at the base of the skull until the skin is visible. Place the tip of the pipette onto the skin and squeeze the pipette several times to empty its contents completely and directly onto the skin in one spot. Avoid contact between the product and your fingers.
Application at the base of the skull will minimise the opportunity for the animal to lick the product. The product should only be apply applied to undamaged skin.
Adverse reactions
Use of the product may result in transient pruritus in cats. On rare occasions greasy fur, erythema and vomiting can occur. These signs disappear without further treatment. The product may, in rare cases, cause local hypersensitivity reactions. If the animal licks the application site after treatment, neurological signs (most of which are transient) may be observed in very rare cases (see section 4.10).
The product tastes bitter. Salivation may occasionally occur if the animal licks the application site immediately after treatment. This is not a sign of intoxication and disappears within some minutes without treatment. Correct application will minimise licking of the application site.
The product may in very rare cases cause at the application site a sensation resulting in transient behavioural changes such as lethargy, agitation, and inappetence.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Similar products
Showing 2 of 2 results
Prinocate (4 - 8 kg)
